CANY
NVAX icon

Caxton Associates (New York)’s Novavax NVAX Stock Holding History

Caxton Associates (New York)’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-73,061
Closed -$923K – 617
2024
Q3 		$923K Buy
+73,061
New +$943K 0.03% 257
2020
Q3 		– Sell
-2,940
Closed -$245K – 454
2020
Q2 		$245K Buy
+2,940
New +$112K 0.02% 321

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Caxton Associates (New York)'s NVAX Position: Q4 2024 in Review

Caxton Associates (New York) sold out of Novavax (NVAX) in Q4 2024, closing a stake of 73,061 shares — an estimated $923K sold.

Caxton Associates (New York) first reported a position in NVAX in Q2 2020 and held it in 2 quarters. The position peaked at $923K in Q3 2024. 234 funds tracked by Wall St. Rank hold NVAX as of Q4 2024.

  • Caxton Associates (New York) reported no remaining Novavax position as of Q4 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 73,061 Novavax shares in Q4 2024, an estimated $923K.
  • Caxton Associates (New York) first reported a position in Novavax in Q2 2020 and held it in 2 quarters.
  • Caxton Associates (New York)'s Novavax position peaked at $923K in Q3 2024.
  • 234 funds tracked by Wall St. Rank held Novavax as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.